Literature DB >> 26251079

Severe, recessive type 1 is a discrete form of von Willebrand disease: the lesson learned from the c.1534-3C>A von Willebrand factor mutation.

A Casonato1, M G Cattini2, G Barbon2, V Daidone2, E Pontara2.   

Abstract

Type 1 von Willebrand disease (VWD) is transmitted mainly as a dominant trait - especially in forms involving von Willebrand factor (VWF) levels below 20 U/dL - and less frequently as a recessive trait. In the latter case, mutations at heterozygous level may be associated with type 3 carrier status, while mutations at homozygous or compound heterozygous level often coincide with type 3 VWD. Here we present a recessive, severe type 1 form as a distinct type of VWD. Eight patients with severe type 1 VWD belonging to 7 unrelated families were studied. They had VWF levels below 10 U/dL, FVIII higher than 10 U/dL, and a significantly lower than normal platelet VWF content. All patients were homozygous or compound heterozygous for the c.1534-3C>A VWF mutation, that simultaneously induces the skipping of exon 14, the activation of a cryptic splice site, and a normal VWF gene transcription. This means that one of the three different mRNA generated assures the synthesis of normal VWF. The probands' relatives who were heterozygous for the c.1534-3C>A mutation always had low platelet VWF levels, sometimes with circulating VWF levels within normal range. This finding confirms the utility of measuring platelet VWF content to identify an abnormal VWF synthesis. Because the c.1534-3C>A mutation impairs, but does not abolish normal mRNA processing, it may never cause type 3 VWD. We propose a model of severe recessive type 1 VWF defect associated with mutations that sporadically go undetected by the cells' molecular machinery, as the c.1534-3C>A VWF mutation. BULLET POINTS: What is known about this topic? - Type 1 VWD is transmitted mainly as a dominant trait. - Recessive type 1 mutations at homozygous or compound heterozygous level are often associated with type 3 VWD, and at heterozygous level with type 3 VWD carrier status. What does this paper add? - There are quantitative VWF mutations, such as c.1534-3C>A, that impair, but do not abolish normal mRNA processing. - The c.1534-3C>A VWF mutation simultaneously induces the skipping of exon 14, the activation of a cryptic splice site, and a normal VWF gene transcription. - The c.1534-3C>A mutation is the archetype of mutations that cause severe recessive type 1 VWD, but never type 3 VWD. - Recessive, severe type 1 appears to be a distinct form of VWD.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26251079     DOI: 10.1016/j.thromres.2015.07.014

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Diagnosing von Willebrand disease: genetic analysis.

Authors:  Anne Goodeve
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 2.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

3.  Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease.

Authors:  Alessandra Casonato; Maria Grazia Cattini; Viviana Daidone; Elena Pontara; Antonella Bertomoro; Paolo Prandoni
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

4.  Cryptic non-canonical splice site activation is part of the mechanism that abolishes multimer organization in the c.2269_2270del von Willebrand factor.

Authors:  Viviana Daidone; Eva Galletta; Luigi De Marco; Alessandra Casonato
Journal:  Haematologica       Date:  2019-07-18       Impact factor: 9.941

5.  von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene.

Authors:  Brooke Sadler; Pamela A Christopherson; Gabe Haller; Robert R Montgomery; Jorge Di Paola
Journal:  Blood       Date:  2021-06-10       Impact factor: 25.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.